FDC Fuglevad Doctors Consultation APS

 

Quicksearch
from your own companies




Analyst: XBRLDenmark
Estimate generation in progress, please wait...
Loading...

Loading...

Loading...

Loading...

Loading...

Loading...

Loading...

Bankruptcy Risk 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Bankruptcy risk for industry  1.5% 1.5% 1.5% 1.5% 1.5%  
Bankruptcy risk  10.4% 17.7% 16.8% 18.6% 23.3%  
Credit score (0-100)  25 8 9 7 2  
Credit rating  BB B BB B B  
Credit limit (kDKK)  0.0 0.0 0.0 0.0 0.0  

How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Net sales  84 41 47 0 0  
Gross profit  69.4 -13.9 -17.5 95.0 -8.7  
EBITDA  69.4 -13.9 -17.5 95.0 -8.7  
EBIT  69.4 -13.9 -17.5 95.0 -8.7  
Pre-tax profit (PTP)  69.2 -78.3 -22.9 78.6 -11.0  
Net earnings  56.7 -78.3 -22.9 76.6 -25.5  
Pre-tax profit without non-rec. items  69.2 -78.3 -22.9 78.6 -11.0  

 
See the entire income statement

Balance sheet (kDKK) 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Tangible assets total  0.0 0.0 0.0 0.0 0.0  
Shareholders equity total  106 27.5 4.6 81.2 55.7  
Interest-bearing liabilities  1.6 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  118 40.0 29.6 107 73.9  

Net Debt  -62.3 -35.9 -14.5 -86.0 -71.9  
 
See the entire balance sheet

Volume 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Net sales  84 41 47 0 0  
Net sales growth  658.4% -51.4% 15.1% -100.0% 0.0%  
Gross profit  69.4 -13.9 -17.5 95.0 -8.7  
Gross profit growth  0.0% 0.0% -26.1% 0.0% 0.0%  
Employees  0 0 0 1 1  
Employee growth %  0.0% 0.0% 0.0% 0.0% 0.0%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  118 40 30 107 74  
Balance sheet change%  12.0% -66.1% -26.0% 262.1% -31.0%  
Added value  69.4 -13.9 -17.5 95.0 -8.7  
Added value %  82.3% -33.8% -37.1% 0.0% 0.0%  
Investments  0 0 0 0 0  

Net sales trend  1.0 -1.0 1.0 -1.0 0.0  
EBIT trend  1.0 -1.0 -2.0 1.0 -1.0  

Profitability 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
EBITDA %  82.3% -33.8% -37.1% 0.0% 0.0%  
EBIT %  82.3% -33.8% -37.1% 0.0% 0.0%  
EBIT to gross profit (%)  100.0% 100.0% 100.0% 100.0% 100.0%  
Net Earnings %  67.4% -191.3% -48.6% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  67.4% -191.3% -48.6% 0.0% 0.0%  
Pre tax profit less extraordinaries %  82.2% -191.3% -48.6% 0.0% 0.0%  
ROA %  62.1% 63.4% -34.8% 119.4% -9.6%  
ROI %  65.2% -115.3% -142.5% 190.5% -12.6%  
ROE %  73.3% -117.6% -142.9% 178.7% -37.3%  

Solidity 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Equity ratio %  89.7% 68.7% 15.4% 75.7% 75.3%  
Relative indebtedness %  14.4% 30.6% 53.1% 0.0% 0.0%  
Relative net indebtedness %  -61.5% -57.2% 22.2% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  -89.8% 259.1% 83.2% -90.5% 825.8%  
Gearing %  1.5% 0.1% 0.0% 0.0% 0.0%  
Net interest  0 0 0 0 0  
Financing costs %  0.4% 73.1% 589.5% 0.0% 0.0%  

Liquidity 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Quick Ratio  7.7 3.2 1.2 4.1 4.0  
Current Ratio  7.7 3.2 1.2 4.1 4.0  
Cash and cash equivalent  63.9 35.9 14.5 86.0 71.9  

Capital use efficiency 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 83.2 141.2 0.0 0.0  
Current assets / Net sales %  110.3% 97.6% 62.8% 0.0% 0.0%  
Net working capital  80.8 27.5 4.6 81.2 55.7  
Net working capital %  95.9% 67.1% 9.7% 0.0% 0.0%  

Employee efficiency 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Net sales / employee  0 0 0 0 0  
Added value / employee  0 0 0 95 -9  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  0 0 0 95 -9  
EBIT / employee  0 0 0 95 -9  
Net earnings / employee  0 0 0 77 -26